ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BTG Btg Plc

840.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Btg Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 840.00 839.00 840.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

BTG PLC Appointment of Non-executive Director (5273X)

27/11/2017 7:00am

UK Regulatory


Btg (LSE:BTG)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Btg Charts.

TIDMBTG

RNS Number : 5273X

BTG PLC

27 November 2017

BTG plc: Appointment of Non-executive Director

London, UK, 27 November 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board.

Greg has a broad range of commercial experience in the US medtech industry, with a focus on interventional medicine therapies. He is currently a non-executive director of Cutera Inc and was previously President and Chief Executive Officer of DFINE Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include leading a minimally invasive surgery division of Boston Scientific, both in US and in emerging markets. Greg has also held a series of senior sales and marketing roles at a number of companies including Baxter Healthcare and C.R. Bard.

Garry Watts, BTG's Chairman, commented: "Greg brings a strong track record to BTG, with significant US commercial and international medtech experience, which will be of great benefit to us as we continue to implement our growth plans."

There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Conduct Authority Listing Rules.

For further information contact:

BTG

Andy Burrows, VP Corporate & Investor Relations

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

Stuart Hunt, Investor Relations Manager

+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

Chris Sampson, Corporate Communications Director

+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178

FTI Consulting

Ben Atwell/Simon Conway

+44 (0)20 3727 1000

About BTG

BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALLFSDLVLRFID

(END) Dow Jones Newswires

November 27, 2017 02:00 ET (07:00 GMT)

1 Year Btg Chart

1 Year Btg Chart

1 Month Btg Chart

1 Month Btg Chart

Your Recent History

Delayed Upgrade Clock